Kyntra Bio (KYNB) risk factors

Item 1A of every Kyntra Bio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open KYNB in Gloom →

Kyntra Bio's chart, financials and news, free in your browser.Open KYNB in Gloom →

FY2025 10-K risk factors
76 risks6 new22 dropped16 reworded
Kyntra Bio highlights risks from single-source roxadustat API suppliers in China and reliance on partners like Astellas and Fortis.
Filed Mar 16, 2026
FY2024 10-K risk factors
92 risks
Roxadustat and FG-3246 drive our business value and commercial success. Drug development faces extensive regulatory review and intense competition globally. Third-party manufacturers and collaborators are critical to our supply chain and clinical success.
Filed Mar 17, 2025